ArticleActive
Response to Comments: MolDX: Breast Cancer Assay: Prosigna (L36811).
A55401
Wisconsin Physicians Service Insurance Corporation (J05)
Effective: February 16, 2017
Updated: December 31, 2025
See LCD L36811Policy Summary
This article (A55401) summarizes comments received on Draft LCD MolDX: Breast Cancer Assay: Prosigna (L36811) and does not itself define coverage indications, limitations, documentation requirements, or frequency limits. For actionable coverage criteria, consult the referenced LCD L36811 and related MolDX policy documents; manual review is recommended.
Coverage Criteria Preview
Key requirements from the full policy
"This article is a response to comments on Draft Local Coverage Determination MolDX: Breast Cancer Assay: Prosigna (L36811) and does not establish coverage indications or limitations; refer to LCD L..."
Sign up to see full coverage criteria, indications, and limitations.